A Comparative Proteomic Approach Using Metabolic Pathways for the Identification of Potential Drug Targets Against Helicobacter Pylori

Overview

Journal Genes Genomics

Specialty Genetics

Date 2020 Mar 21

PMID 32193857

Citations 4

Authors

Reaz Uddin

Waqar Khalil

Affiliations

Soon will be listed here.

Abstract

Background: Helicobacter pylori is the most highlighted pathogen across the globe especially in developing countries. Severe gastric problems like ulcers, cancers are associated with H. pylori and its prevalence is widespread. Evolution in the genome and cross-resistance with different antibiotics are the major reason of its survival and pandemic resistance against current regimens.

Objectives: To prioritize potential drug target against H. pylori by comparing metabolic pathways of its available strains.

Methods: We used various computational tools to extract metabolic sets of all available (61) strains of H. pylori and performed pan genomics and subtractive genomics analysis to prioritize potential drug target. Additionally, the protein interaction and detailed structure-based studies were performed for further characterization of protein.

Results: We found 41 strains showing similar set of metabolic pathways. However, 19 strains were found with unique set of metabolic pathways. The metabolic set of these 19 strains revealed 83 unique proteins and BLAST against human proteome further funneled them to 38 non-homologous proteins. The druggability and essentiality testing further converged our findings to a single unique protein as a potential drug target against H. pylori.

Conclusion: We prioritized one protein-based drug target which upon subject to applied protocol was found as close homolog of the Saccharopine dehydrogenase. Our study has opened further avenues of research regarding the discovery of new drug targets against H. pylori.

Citing Articles

Screening Marine Microbial Metabolites as Promising Inhibitors of : A Structural Docking Approach towards Developing Novel Lyme Disease Treatment.

Basharat Z, Sattar S, Bahauddin A, Al Mouslem A, Alotaibi G Biomed Res Int. 2024; 2024:9997082.

PMID: 38456098 PMC: 10919988. DOI: 10.1155/2024/9997082.

Exploring the inhibitory potential of -designed small peptides on Hp0231 (DsbK), a periplasmic oxidoreductase involved in disulfide bond formation.

Roszczenko-Jasinska P, Gieldon A, Mazur D, Spodzieja M, Plichta M, Czaplewski C Front Mol Biosci. 2024; 10:1335704.

PMID: 38274095 PMC: 10810133. DOI: 10.3389/fmolb.2023.1335704.

Proteogenomic analysis of Serratia marcescens using computational subtractive genomics approach.

DSouza S, Khan K, Uddin R PLoS One. 2023; 18(4):e0283993.

PMID: 37036837 PMC: 10085029. DOI: 10.1371/journal.pone.0283993.

Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.

Roszczenko-Jasinska P, Wojtys M, Jagusztyn-Krynicka E Appl Microbiol Biotechnol. 2020; 104(23):9891-9905.

PMID: 33052519 PMC: 7666284. DOI: 10.1007/s00253-020-10945-w.

References

Luo H, Lin Y, Gao F, Zhang C, Zhang R . DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res. 2013; 42(Database issue):D574-80. PMC: 3965060. DOI: 10.1093/nar/gkt1131. View

Uddin R, Saeed K, Khan W, Azam S, Wadood A . Metabolic pathway analysis approach: identification of novel therapeutic target against methicillin resistant Staphylococcus aureus. Gene. 2014; 556(2):213-26. DOI: 10.1016/j.gene.2014.11.056. View

Shiomi S, Toriie A, Imamura S, Konishi H, Mitsufuji S, Iwakura Y . IL-17 is involved in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Helicobacter. 2009; 13(6):518-24. PMC: 2631559. DOI: 10.1111/j.1523-5378.2008.00629.x. View

Savoldi A, Carrara E, Graham D, Conti M, Tacconelli E . Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018; 155(5):1372-1382.e17. PMC: 6905086. DOI: 10.1053/j.gastro.2018.07.007. View

Jones P, Binns D, Chang H, Fraser M, Li W, McAnulla C . InterProScan 5: genome-scale protein function classification. Bioinformatics. 2014; 30(9):1236-40. PMC: 3998142. DOI: 10.1093/bioinformatics/btu031. View

Neshich I, Kiyota E, Arruda P . Genome-wide analysis of lysine catabolism in bacteria reveals new connections with osmotic stress resistance. ISME J. 2013; 7(12):2400-10. PMC: 3834855. DOI: 10.1038/ismej.2013.123. View

Uddin R, Saeed K . Identification and characterization of potential drug targets by subtractive genome analyses of methicillin resistant Staphylococcus aureus. Comput Biol Chem. 2013; 48:55-63. DOI: 10.1016/j.compbiolchem.2013.11.005. View

Fan X, Gunasena H, Cheng Z, Espejo R, Crowe S, Ernst P . Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J Immunol. 2000; 165(4):1918-24. DOI: 10.4049/jimmunol.165.4.1918. View

Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K . KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2016; 45(D1):D353-D361. PMC: 5210567. DOI: 10.1093/nar/gkw1092. View

10.

Kusters J, Van Vliet A, Kuipers E . Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006; 19(3):449-90. PMC: 1539101. DOI: 10.1128/CMR.00054-05. View

11.

Wang L, Lin Z, Chen S, Li J, Chen C, Huang Z . Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. Clin Microbiol Infect. 2017; 23(6):391-395. DOI: 10.1016/j.cmi.2016.12.032. View

12.

Malfertheiner P, Megraud F, OMorain C, Gisbert J, Kuipers E, Axon A . Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2016; 66(1):6-30. DOI: 10.1136/gutjnl-2016-312288. View

13.

Garg V, Avashthi H, Tiwari A, Jain P, Ramkete P, Kayastha A . MFPPI - Multi FASTA ProtParam Interface. Bioinformation. 2017; 12(2):74-77. PMC: 5237651. DOI: 10.6026/97320630012074. View

14.

Zamani M, Ebrahimtabar F, Zamani V, Miller W, Alizadeh-Navaei R, Shokri-Shirvani J . Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018; 47(7):868-876. DOI: 10.1111/apt.14561. View

15.

Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K . BLAST+: architecture and applications. BMC Bioinformatics. 2009; 10:421. PMC: 2803857. DOI: 10.1186/1471-2105-10-421. View

16.

Solnick J, Schauer D . Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev. 2001; 14(1):59-97. PMC: 88962. DOI: 10.1128/CMR.14.1.59-97.2001. View

17.

Yu N, Wagner J, Laird M, Melli G, Rey S, Lo R . PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics. 2010; 26(13):1608-15. PMC: 2887053. DOI: 10.1093/bioinformatics/btq249. View

18.

Tursi A, Di Mario F, Franceschi M, De Bastiani R, Elisei W, Baldassarre G . New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice. Helicobacter. 2017; 22(3). DOI: 10.1111/hel.12371. View

19.

Dooley C, Cohen H, Fitzgibbons P, Bauer M, APPLEMAN M, Perez-Perez G . Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med. 1989; 321(23):1562-6. DOI: 10.1056/NEJM198912073212302. View

20.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View